LON:IQAIIQ-AI Share Price, Forecast & News

IQ-AI's stock was trading at GBX 2.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IQAI shares have increased by 10.6% and is now trading at GBX 3.13. View which stocks have been most impacted by Coronavirus.

News coverage about IQAI stock has trended neutral this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. IQ-AI earned a coverage optimism score of 0.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the stock's share price in the next several days. View the latest news about IQ-AI.

Based on aggregate information from My MarketBeat watchlists, some companies that other IQ-AI investors own include Macerich (MAC), Merck & Co., Inc. (MRK), Pfizer (PFE), Scotts Miracle-Gro (SMG), Xilinx (XLNX), Arista Networks (ANET), Amgen (AMGN), Advanced Micro Devices (AMD), Akers Biosciences (AKER) and Aimmune Therapeutics (AIMT).

IQ-AI trades on the London Stock Exchange (LON) under the ticker symbol "IQAI."

Shares of IQAI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

One share of IQAI stock can currently be purchased for approximately GBX 3.13.

IQ-AI has a market capitalization of £4.56 million and generates £267,868.00 in revenue each year.